SynBioBeta Speaker

Krish Ramadurai

AIX Ventures

Partner

Krish is a Partner at AIX Ventures, where he leads technical due diligence, investment sourcing, and portfolio operations across the firm's AI, healthcare, and life sciences practices. He has led and managed over 40 early- and growth-stage investments across multiple top-decile performing funds, driving a cumulative portfolio enterprise value exceeding $20 billion. His investment track record includes notable exits such as Volumetric Biotechnologies (acquired by 3D Systems), PathologyWatch (acquired by Sonic Healthcare), Trials. AI (acquired by ZS Associates), and Insilico Medicine (IPO announced). Krish has backed several unicorn companies and supported over 20 major scientific breakthroughs, including the world's first AI-designed drug to reach human trials and the first therapeutic discovered using a 3D-bioprinted tissue disease model.‍Krish is a Harvard- and Oxford-trained research scientist and biomolecular engineer, multi-published author, advisor, lecturer, and a former researcher at Harvard and MIT. While at Harvard’s Belfer Center for Science and International Affairs & Taubman Center for State and Local Government, he worked alongside former U. S. Secretary of Defense Ash Carter and Nobel Laureate Economist Michael Kremer on the USAID Development Innovation Ventures Fund. During this time, he published three internationally released books on applied engineering and medicine, featured in Barnes & Noble, the National Institute of Health (NIH), and the library collections of Oxford, MIT, Harvard, Yale, and Princeton.‍Krish has been a board member for numerous leading AI-enabled health and techbio companies and is a venture advisor for Nucleate and the National Venture Capital Association (NVCA) Venture Forward Program. He is also a member of Oxford University’s Institute of Biomedical Engineering (IBME), the American Society of Biomechanics (ASB), the American Institute of Chemical Engineers (AIChE), and the Advanced Research Projects Agency for Health (ARPA-H). His thought leadership has been featured in leading media outlets, including the Wall Street Journal, Venture Capital Journal, Yahoo Finance, TechCrunch, Business Insider, the World Economic Forum, and Nikkei Asia. ‍

SynBioBeta 2026 Tickets are Live

Confirmed Speakers

Sessions Featuring

Krish

This Year

Breakout Session

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Purchase Pass

Breakout Session

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Purchase Pass

TBD

Session lineup still growing

Purchase Pass

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Purchase Pass

Featuring

Speaker Coming Soon

Previous Speakers Include